This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact The Epoch Times Reprints.
A new clinical option could potentially help hospitals quicken how sepsis is assessed and treated, thereby improving patient outcome.
Hospital records show Zosyn is more likely to lead to death than other treatments for sepsis.
Recent research has found that sepsis is more common and lethal among COVID-19 patients than previously thought.
Standard intravenous antibiotic therapies often prove futile against sepsis’ complex nature. Yet new hope may be found in an unlikely place.
